149 related articles for article (PubMed ID: 17101596)
41. Decreased expression of CD69 in chronic fatigue syndrome in relation to inflammatory markers: evidence for a severe disorder in the early activation of T lymphocytes and natural killer cells.
Mihaylova I; DeRuyter M; Rummens JL; Bosmans E; Maes M
Neuro Endocrinol Lett; 2007 Aug; 28(4):477-83. PubMed ID: 17693977
[TBL] [Abstract][Full Text] [Related]
42. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma.
Siddiqui SA; Frigola X; Bonne-Annee S; Mercader M; Kuntz SM; Krambeck AE; Sengupta S; Dong H; Cheville JC; Lohse CM; Krco CJ; Webster WS; Leibovich BC; Blute ML; Knutson KL; Kwon ED
Clin Cancer Res; 2007 Apr; 13(7):2075-81. PubMed ID: 17404089
[TBL] [Abstract][Full Text] [Related]
43. Evidence-based radiation oncology in head and neck squamous cell carcinoma.
Corvò R
Radiother Oncol; 2007 Oct; 85(1):156-70. PubMed ID: 17482300
[TBL] [Abstract][Full Text] [Related]
44. PET monitoring of therapy response in head and neck squamous cell carcinoma.
Schöder H; Fury M; Lee N; Kraus D
J Nucl Med; 2009 May; 50 Suppl 1():74S-88S. PubMed ID: 19380408
[TBL] [Abstract][Full Text] [Related]
45. A correlative analysis of in vitro parameters of cellular immunity in patients with squamous cell carcinoma of the head and neck.
Deegan MJ; Coulthard SW; Quaiman SJ; Schork MA
Cancer Res; 1977 Dec; 37(12):4475-81. PubMed ID: 144562
[No Abstract] [Full Text] [Related]
46. Metastatic cutaneous squamous cell carcinoma of the head and neck: the Immunosuppression, Treatment, Extranodal spread, and Margin status (ITEM) prognostic score to predict outcome and the need to improve survival.
Oddone N; Morgan GJ; Palme CE; Perera L; Shannon J; Wong E; Gebski V; Veness MJ
Cancer; 2009 May; 115(9):1883-91. PubMed ID: 19224549
[TBL] [Abstract][Full Text] [Related]
47. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
[TBL] [Abstract][Full Text] [Related]
48. DNA ploidy, proliferative capacity and intratumoral heterogeneity in primary and recurrent head and neck squamous cell carcinomas (HNSCC)--potential implications for clinical management and treatment decisions.
Hass HG; Schmidt A; Nehls O; Kaiser S
Oral Oncol; 2008 Jan; 44(1):78-85. PubMed ID: 17350326
[TBL] [Abstract][Full Text] [Related]
49. Association study of the G-protein beta3 subunit C825T polymorphism with disease progression an overall survival in patients with head and neck squamous cell carcinoma.
Lehnerdt GF; Franz P; Bankfalvi A; Grehl S; Jahnke K; Lang S; Schmid KW; Siffert W; Frey UH
Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3203-7. PubMed ID: 18990763
[TBL] [Abstract][Full Text] [Related]
50. Increased sensitivity to bleomycin in upper aerodigestive tract mucosa of head and neck squamous cell carcinoma patients.
Jin C; Jin Y; Wennerberg J; Rosenquist B; Mertens F
Mutat Res; 2008 Mar; 652(1):30-7. PubMed ID: 18243046
[TBL] [Abstract][Full Text] [Related]
51. Sphingosine-1-phosphate reduces CD4+ T-cell activation in type 1 diabetes through regulation of hypoxia-inducible factor short isoform I.1 and CD69.
Srinivasan S; Bolick DT; Lukashev D; Lappas C; Sitkovsky M; Lynch KR; Hedrick CC
Diabetes; 2008 Feb; 57(2):484-93. PubMed ID: 18003758
[TBL] [Abstract][Full Text] [Related]
52. Galectins as modulators of tumor progression in head and neck squamous cell carcinomas.
Saussez S; Camby I; Toubeau G; Kiss R
Head Neck; 2007 Sep; 29(9):874-84. PubMed ID: 17315170
[TBL] [Abstract][Full Text] [Related]
53. The flow cytometric analysis of premalignant and malignant lesions in head and neck squamous cell carcinoma.
Abou-Elhamd KE; Habib TN
Oral Oncol; 2007 Apr; 43(4):366-72. PubMed ID: 16931118
[TBL] [Abstract][Full Text] [Related]
54. Lymphocyte subpopulations infiltrating squamous carcinomas of the head and neck: correlations with extent of tumor and prognosis.
Wolf GT; Hudson JL; Peterson KA; Miller HL; McClatchey KD
Otolaryngol Head Neck Surg; 1986 Sep; 95(2):142-52. PubMed ID: 2954014
[TBL] [Abstract][Full Text] [Related]
55. Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE).
Bonelli M; Savitskaya A; von Dalwigk K; Steiner CW; Aletaha D; Smolen JS; Scheinecker C
Int Immunol; 2008 Jul; 20(7):861-8. PubMed ID: 18469329
[TBL] [Abstract][Full Text] [Related]
56. Serum protein profile analysis following definitive treatment in patients with head and neck squamous cell carcinoma.
Gourin CG; Moretz WH; Weinberger PM; Xia ZS; Liu Z; Terris DJ; Adam BL
Arch Otolaryngol Head Neck Surg; 2007 Nov; 133(11):1125-30. PubMed ID: 18025317
[TBL] [Abstract][Full Text] [Related]
57. External validation of a risk group defined by recursive partitioning analysis in patients with head and neck carcinoma treated with surgery and postoperative radiotherapy.
León X; López M; Piñeiro Z; Langendijk JA; Leemans CR; Quer M
Head Neck; 2007 Sep; 29(9):815-21. PubMed ID: 17405168
[TBL] [Abstract][Full Text] [Related]
58. T-cell activation in occupational asthma and rhinitis.
Mamessier E; Milhe F; Guillot C; Birnbaum J; Dupuy P; Lorec AM; Vervloet D; Magnan A
Allergy; 2007 Feb; 62(2):162-9. PubMed ID: 17298425
[TBL] [Abstract][Full Text] [Related]
59. Potential stem cell marker CD44 is constitutively expressed in permanent cell lines of head and neck cancer.
Pries R; Witrkopf N; Trenkle T; Nitsch SM; Wollenberg B
In Vivo; 2008; 22(1):89-92. PubMed ID: 18396788
[TBL] [Abstract][Full Text] [Related]
60. Activated T lymphocytes in pre-eclampsia.
Darmochwal-Kolarz D; Saito S; Rolinski J; Tabarkiewicz J; Kolarz B; Leszczynska-Gorzelak B; Oleszczuk J
Am J Reprod Immunol; 2007 Jul; 58(1):39-45. PubMed ID: 17565546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
